EGFR-mutated lung adenocarcinoma accompanied by RB1 and TP53 mutations represents the highest-risk group for SCLC transformation during targeted therapy, with a transformation probability of up to 18%. The gene discussed is RB1; the disease is lung adenocarcinoma.